AstraZeneca shares: 4 reasons I’d buy them now

The AZN share price has been subdued for the last few months, but Manika Premsingh thinks that’s about to change. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Its latest financial update hasn’t sent the AstraZeneca (LSE: AZN) share price soaring, but it has underlined why the share was one of last year’s star stocks. 

AZN share in focus 

AstraZeneca had been a performer at the stock markets even earlier, but last year put it directly under the spotlight. As the market crash occurred last March, panicked investors rushed towards safer stocks, like ones in the healthcare sector. The AstraZeneca share was so much in demand that by August, it touched all-time highs. 

It dominated the news because of its Covid-19 vaccine, too. Developed along with the University of Oxford, it has quite literally been a life-saver. As this and other vaccines were successfully developed, investor confidence returned, and the stock market rally began. 

It fell a bit out of favour as investors’ confidence returned in November. However, the AZN share price has only fallen from its new high levels. In 2021 so far it’s only about 6.5% lower on average than it was in all of 2020. 

The stock can rise further 

In fact, I think, going by both the share’s price trajectory over time and the company’s performance, that it can rise again. There are four reasons behind my thinking. 

One, its results, which were released today. It has shown double-digit growth for both the full-year 2020 and the fourth-quarter of the year today. It also expects to continue showing a similar performance next year, although that is not certain, of course. Its core earnings per share (EPS) is up as well.  

Two, speaking of EPS, AstraZeneca also pays a dividend. At present, the AstraZeneca share has a yield of around 3%. For 2021, it will maintain dividends at the current levels. But as a long-term investor, I’m hopeful for future increases in dividend if the EPS keeps rising. A growth stock with increasing dividends sounds good to me. 

Competitive share price for AZN

Three, a relatively subdued share price and an increase in earnings also means that the price-to-earnings ratio (P/E) has also decreased. AZN now trades at 38 times. If I compare this to stocks like the FTSE 100 water and wastewater services provider United Utilities (UU), it looks relatively inexpensive. UU has an earnings ratio of almost 57 times. Similarly, Severn Trent (SVT) has a ratio of 48 times. 

Four brings me to the future share price potential. If we think that the value of UU and SVT is the price associated with safe and financially healthy defensives, then the AZN share price can be expected to rise in the near future. 

Risks and takeaway

There are, of course, always risks to buying any stock. The global economy isn’t out of the woods yet, AZN’s own vaccine isn’t effective against the South African coronavirus variants, and there’s always the possibility of another market crash. But on balance, I’m more in favour of the AZN share than not. In fact, it was my top stock for this month based on expectations of the good results that we saw today. It’s a good stock for me to buy. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

FTSE shares: how £500 a month could put investors on the path to becoming millionaires

By consistently investing in FTSE shares, investors can accelerate their journey to millionaire status even if they only have £500…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

£10 a day invested in cheap LSE shares could unlock a second income of £27,125 a year!

Believe it or not, investing just £10 a day can potentially unlock high returns and an attractive passive income stream…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

Down 90%, is this growth stock finally worth buying in July?

This burgeoning robotics growth stock's been struggling with mounting losses, but could that soon be about to change? Zaven Boyrazian…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Could the Lloyds share price come crashing down?

In 2025, the Lloyds share price has hit heights not seen for a decade. Dr James Fox explores where the…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Income shares: how much do I need to invest to earn £500 a month?

With a monthly passive income goal of £500, Zaven Boyrazian breaks down how much he thinks investors need to put…

Read more »

Modern apartments on both side of river Irwell passing through Manchester city centre, UK.
Investing Articles

2 overlooked UK shares to consider for dividends

Paul Summers looks beyond the usual suspects from the FTSE 100 and highlights two under-the-radar UK shares offering great passive…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

Prediction: in 12 months the hated Ocado share price could turn £10,000 into…

Harvey Jones is desperate for some good news about the beleaguered Ocado share price, and he finally appears to have…

Read more »

A young Asian woman holding up her index finger
Investing Articles

Up 132% in 2025! Is this one of the best growth shares to buy today?

Looking for the best shares to buy now? This soaring mining enterprise has dominated in 2025, beating the FTSE 100…

Read more »